Biotechnology News

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 ...

ボストンおよびストックホルム発, Jan. 29, 2026 (GLOBE NEWSWIRE) -- 先進的イムノアッセイに特化した世界的なライフサイエンスツール企業であるマブテック (Mabtech) と、主要な統合型医薬品研究開発製造受託機関 (CRDMO) であるサイ・ライフ・サイエンシズ (Sai Life Sciences)...

MELBOURNE, Australia, Jan. 29, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic...

Alvotech (NASDAQ: ALVO, ALVO SDB) hefur náð samningi við frumlyfjafyrirtækin Regeneron og Bayer sem leysir endanlega úr öllum ágreiningi um hugverkaréttindi þeirra fyrir augnlyfið Eylea (aflibercept 2...

REYKJAVIK, ICELAND (January 29, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today...

REYKJAVIK, Iceland, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients...

OSE Immunotherapeutics sélectionne la pouchite chronique et l’hidradénite suppurée comme nouvelles indications clés pour Lusvertikimab Développement basé sur un fort rationnel biologique de...

OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation...

- Phase 1b clinical site start-up and regulatory activities in Australia underway to support the global registrational program - HUNTSVILLE, AL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Serina...